Sanofi Mounts Offensive For Eloxatin
Eloxatin is once again the subject of heavy litigation now that Sanofi-Aventis U.S. LLC has slammed generics makers with patent infringement suits over the hit colon cancer drug, just days after...To view the full article, register now.
Already a subscriber? Click here to view full article